The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.
Related to this article
In a recent OncLive Peer Exchange, expert investigators discussed the utility of ctDNA and MRD testing in solid tumors.
The European Union approved trastuzumab deruxtecan for previously treated, HER2-postive metastatic solid tumors.
The top 5 OncLive TV videos of the week cover insights in breast cancer, lymphoma, melanoma, prostate cancer, and ovarian cancer.
The FDA has approved new sacituzumab govitecan indications in TNBC, cleared palbociclib combination maintenance treatment in HER2-positive breast cancer, and more.
The European Commission has approved epcoritamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma.
Zanubrutinib plus R-BAP produced responses in both younger and older patients with previously untreated mantle cell lymphoma.
Breast oncologists weigh the future role of radiographic progression vs liquid biopsy in the timing of therapeutic shifts in metastatic breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
How Bispecific T-Cell Engager Therapy Works and Why HLA Status Is Non-Negotiable
2
Northwestern Medicine Study Finds Lung Transplant Dramatically Improves Survival for Patients With Terminal Lung Cancer
3
STRIDE Plus TACE With/Without Lenvatinib Improves Responses in Embolization-Eligible HCC
4
Dr Spencer on the Potential Role for In Vivo CAR T-Cell Therapy in Myeloma
5